welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders
PTC Therapeutics, Inc. today announced the three funding recipients from PRIORITY, an annual program to support outstanding clinical research by the rare genetic disorders community. This year’s funding will accelerate innovative research projects to improve Duchenne muscular dystrophy screening in infants and support earlier diagnosis of this progressive, muscle-wasting disease.
“We were overwhelmed to receive so many outstanding applications in the first year of PRIORITY and to see such a breadth of ideas to improve the screening and diagnosis of Duchenne,” said Dr. Claudio Santos, Senior Vice President, Global Medical Affairs, PTC Therapeutics, Inc. “We are thrilled that the PRIORITY program will help bring these research projects to fruition and ultimately help patients receive the best care as early as possible.”
rareRelated
-
Coalition DuchenneThe mission of Coalition Duchenne is to ...
-
FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular D...FibroGen, Inc., a leading biopharmaceu...
-
A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersen, Eteplirsen and Golodirsen in Subject...This is an 48-week open-label study to d...
-
Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophyIn Duchenne muscular dystrophy (DMD), pr...
-
Utrophin modulators to treat Duchenne muscular dystrophy (DMD): Phase 1b Clinical Trial Results of SMT C1100Objective: To assess the safety, tolera...
-
Mallinckrodt’s MNK-1411 gets orphan drug status for DMDMallinckrodt plc MNK announced that the ...
-
Exploratory Study of NS-089/NCNP-02 in DMDThis study is designed to assess the saf...
